Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 14, 2023

BUY
$2.78 - $8.09 $75,201 - $218,842
27,051 New
27,051 $94,000
Q1 2022

May 13, 2022

SELL
$5.05 - $7.7 $59,337 - $90,475
-11,750 Closed
0 $0
Q4 2021

Feb 14, 2022

BUY
$7.13 - $15.19 $83,777 - $178,482
11,750 New
11,750 $91,000

Others Institutions Holding LYEL

About Lyell Immunopharma, Inc.


  • Ticker LYEL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 247,824,992
  • Market Cap $151M
  • Description
  • Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate...
More about LYEL
Track This Portfolio

Track Alpine Global Management, LLC Portfolio

Follow Alpine Global Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Alpine Global Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Alpine Global Management, LLC with notifications on news.